Valuation: Teva Pharmaceutical Industries Limited

Market Cap 46.05B 40.25B 37.83B 34.52B 64.78B 4,402B 64.8B 454B 175B 2,248B 173B 169B 7,248B P/E 2026 *
66.7x
P/E 2027 * 20.1x
Enterprise Value 57.42B 50.18B 47.16B 43.04B 80.77B 5,489B 80.79B 566B 218B 2,803B 216B 211B 9,037B EV / Sales 2026 *
3.44x
EV / Sales 2027 * 3.16x
Free-Float
91.2%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 31/12/2022
Director of Finance/CFO 53 21/12/2019
Chief Operating Officer 52 02/06/2024
Director TitleAgeSince
Director/Board Member 69 31/12/2008
Chairman 78 05/02/2017
Director/Board Member 65 31/08/2015
Change 5-day change 1-year change 3-year change Capi.($)
+239.73%0.00% - - 46.05B
-0.35%+2.53%+56.17%+111.22% 1,043B
+0.80%+1.76%+54.03%+69.71% 649B
+1.05%+2.39%+20.74%+73.81% 469B
+0.43%+1.19%+38.31%+46.98% 355B
+1.46%+3.76%+21.60%+28.19% 270B
-0.98%+3.71%+11.80%+12.44% 262B
+0.38%+10.42%+44.90%+55.73% 222B
+0.38%+4.22%+34.54%+105.69% 189B
-1.56%-6.27%-31.77%-59.90% 175B
Average +0.18%+2.20%+27.81%+49.32% 403.67B
Weighted average by Cap. +0.24%+2.19%+37.65%+67.50%

Financials

2026 *2027 *
Net sales 16.68B 14.57B 13.7B 12.5B 23.46B 1,594B 23.46B 164B 63.43B 814B 62.62B 61.25B 2,624B 17.32B 15.13B 14.22B 12.98B 24.36B 1,655B 24.37B 171B 65.87B 845B 65.03B 63.61B 2,725B
Net income 1.25B 1.09B 1.03B 938M 1.76B 120B 1.76B 12.34B 4.76B 61.1B 4.7B 4.6B 197B 2.44B 2.13B 2B 1.83B 3.43B 233B 3.43B 24.06B 9.29B 119B 9.17B 8.97B 384B
Net Debt 11.37B 9.93B 9.34B 8.52B 15.99B 1,087B 15.99B 112B 43.24B 555B 42.69B 41.75B 1,789B 8.71B 7.61B 7.15B 6.52B 12.25B 832B 12.25B 85.81B 33.11B 425B 32.69B 31.98B 1,370B
Logo Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
A
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!